MX2022011123A - Compuestos inhibidores de phd, composiciones, y uso. - Google Patents
Compuestos inhibidores de phd, composiciones, y uso.Info
- Publication number
- MX2022011123A MX2022011123A MX2022011123A MX2022011123A MX2022011123A MX 2022011123 A MX2022011123 A MX 2022011123A MX 2022011123 A MX2022011123 A MX 2022011123A MX 2022011123 A MX2022011123 A MX 2022011123A MX 2022011123 A MX2022011123 A MX 2022011123A
- Authority
- MX
- Mexico
- Prior art keywords
- pulmonary
- disease
- phd
- kidney
- acute
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 208000007788 Acute Liver Failure Diseases 0.000 abstract 1
- 206010000804 Acute hepatic failure Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 231100000836 acute liver failure Toxicity 0.000 abstract 1
- 206010069351 acute lung injury Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000018578 heart valve disease Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona, en parte, nuevos inhibidores de moléculas pequeñas de PHD, que tienen una estructura de acuerdo con la Fórmula (A), y subfórmulas de estos: (ver fórmula) o una sal farmacéuticamente aceptable de estos. Los compuestos proporcionados en la presente descripción pueden ser útiles para el tratamiento de enfermedades que incluyen la enfermedad cardíaca (p. ej., enfermedad cardíaca isquémica, insuficiencia cardíaca congestiva y enfermedad cardíaca valvular), pulmonar (p. ej., lesión pulmonar aguda, hipertensión pulmonar, fibrosis pulmonar y enfermedad pulmonar obstructiva crónica), hepática (p. ej., insuficiencia hepática aguda y fibrosis hepática y cirrosis), y renal (p. ej., lesión renal aguda y enfermedad renal crónica).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992585P | 2020-03-20 | 2020-03-20 | |
| PCT/US2021/023219 WO2021188936A1 (en) | 2020-03-20 | 2021-03-19 | Phd inhibitor compounds, compositions, and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011123A true MX2022011123A (es) | 2023-01-04 |
Family
ID=75639962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011123A MX2022011123A (es) | 2020-03-20 | 2021-03-19 | Compuestos inhibidores de phd, composiciones, y uso. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230227426A1 (es) |
| EP (1) | EP4121425A1 (es) |
| JP (2) | JP7768890B2 (es) |
| KR (1) | KR20220156889A (es) |
| CN (2) | CN119823097A (es) |
| AR (1) | AR121618A1 (es) |
| AU (1) | AU2021239378A1 (es) |
| BR (1) | BR112022018877A2 (es) |
| CA (1) | CA3176140A1 (es) |
| CO (1) | CO2022014490A2 (es) |
| IL (1) | IL296631A (es) |
| MX (1) | MX2022011123A (es) |
| TW (1) | TW202140443A (es) |
| WO (1) | WO2021188936A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| WO2021117767A1 (ja) | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
| CN115991698B (zh) * | 2022-11-03 | 2024-03-29 | 广东中科药物研究有限公司 | 一种杂环化合物及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EA031647B1 (ru) | 2013-03-29 | 2019-02-28 | Такеда Фармасьютикал Компани Лимитед | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd |
-
2021
- 2021-03-19 AR ARP210100691A patent/AR121618A1/es unknown
- 2021-03-19 MX MX2022011123A patent/MX2022011123A/es unknown
- 2021-03-19 AU AU2021239378A patent/AU2021239378A1/en active Pending
- 2021-03-19 WO PCT/US2021/023219 patent/WO2021188936A1/en not_active Ceased
- 2021-03-19 TW TW110109982A patent/TW202140443A/zh unknown
- 2021-03-19 JP JP2022556170A patent/JP7768890B2/ja active Active
- 2021-03-19 CN CN202510216379.8A patent/CN119823097A/zh active Pending
- 2021-03-19 CA CA3176140A patent/CA3176140A1/en active Pending
- 2021-03-19 EP EP21720873.5A patent/EP4121425A1/en active Pending
- 2021-03-19 US US17/906,650 patent/US20230227426A1/en active Pending
- 2021-03-19 KR KR1020227036362A patent/KR20220156889A/ko active Pending
- 2021-03-19 IL IL296631A patent/IL296631A/en unknown
- 2021-03-19 CN CN202180034124.XA patent/CN115551845B/zh active Active
- 2021-03-19 BR BR112022018877A patent/BR112022018877A2/pt unknown
-
2022
- 2022-10-12 CO CONC2022/0014490A patent/CO2022014490A2/es unknown
-
2025
- 2025-10-30 JP JP2025183157A patent/JP2026021443A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021239378A1 (en) | 2022-11-17 |
| TW202140443A (zh) | 2021-11-01 |
| CN115551845A (zh) | 2022-12-30 |
| CA3176140A1 (en) | 2021-09-23 |
| US20230227426A1 (en) | 2023-07-20 |
| CO2022014490A2 (es) | 2022-10-21 |
| EP4121425A1 (en) | 2023-01-25 |
| JP2023518953A (ja) | 2023-05-09 |
| AR121618A1 (es) | 2022-06-22 |
| WO2021188936A1 (en) | 2021-09-23 |
| CN119823097A (zh) | 2025-04-15 |
| KR20220156889A (ko) | 2022-11-28 |
| CN115551845B (zh) | 2025-02-28 |
| JP7768890B2 (ja) | 2025-11-12 |
| JP2026021443A (ja) | 2026-02-10 |
| IL296631A (en) | 2022-11-01 |
| BR112022018877A2 (pt) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014490A2 (es) | Compuestos inhibidores de phd, composiciones y uso | |
| CO2022014587A2 (es) | Compuestos inhibidores de phd, composiciones y uso | |
| ECSP10010242A (es) | Compuestos organicos | |
| CY1122860T1 (el) | 3,5-διαμινο-6-χλωρο-ν-(ν-(4-(4-(2-(εξυλ(2,3,4,5,6-πενταϋδροξυεξυλ)αμινο)αιθοξυ)φαινυλ)βουτυλ)καρβαμιμιδοϋλ)πυραζινο-2-καρβοξαμιδιο | |
| AR121626A1 (es) | Compuestos inhibidores de phd, composiciones y métodos de uso | |
| JP2017526636A5 (es) | ||
| PE20210046A1 (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil peptido | |
| AR111178A1 (es) | Inhibidor de la quinasa reguladora de la señal de apoptosis | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| JP2009544602A5 (es) | ||
| MX2009001659A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea. | |
| JP2008546770A5 (es) | ||
| CL2023002616A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR127507A1 (es) | Agonistas de rxfp1 | |
| MX2024011179A (es) | Compuestos multiciclicos | |
| AR134363A1 (es) | Derivado de ácido 2-(pirrolidina-3-il)acético sustituido, método de preparación y uso de este | |
| DOP2025000101A (es) | Derivados de benzimidazol cíclico como inhibidores de cgas | |
| AR123243A1 (es) | Compuestos inhibidores del phd, composiciones y métodos de uso | |
| NO20081736L (no) | Antitumormidler | |
| CY1112480T1 (el) | Χρηση παραγωγων συμπυκνωμενης πυριμιδινης για τη θεραπεια αυτοανοσων και φλεγμονωδων ασθενειων | |
| CN115066417A (zh) | 凝血因子XIa抑制剂 | |
| BR112023000344A2 (pt) | Agonistas de receptor de peptídeo de formila de pirazolona 2 | |
| JP2020503267A5 (es) | ||
| MX2022004809A (es) | Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc). | |
| AR131016A1 (es) | DERIVADOS DE BENZIMIDAZOL CÍCLICO COMO INHIBIDORES DE cGAS |